Search

Statement of Solidarity after Earthquake in Morocco

On behalf of the European Hematology Association, I would like to express my deepest condolences and heartfelt support to the people of Morocco who have been affected by the recent earthquake.

Read more

Adding elotuzumab to standard treatment for multiple myeloma significantly reduced the risk of disease progression, with benefits sustained at two years

ELOQUENT-2, which evaluated elotuzumab in combination with lenalidomide and dexamethasone, is the first Phase III study to demonstrate the benefit of directly activating the immune system in the treatment of patients with relapsed or refractory multiple myeloma.

Read more